Malta - English - Medicines Authority

reddy pharma iberia s.a. avinguda de josep tarradellas 38 barcelona, 08029, spain - powder for solution for injection/infusion - daptomycin 500 mg - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 5 mg (equivalent: ondansetron, qty 4 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 10 mg (equivalent: ondansetron, qty 8 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - zolpidem tartrate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate; hypromellose; magnesium stearate; titanium dioxide; macrogol 400 - short-term treatment of insomnia in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - ondansetron, quantity: 8 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; microcrystalline cellulose; guar gum; crospovidone; sodium lauryl sulfate; colloidal anhydrous silica; mannitol; aspartame; pregelatinised maize starch; flavour - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - ondansetron, quantity: 4 mg - tablet, orally disintegrating - excipient ingredients: crospovidone; magnesium stearate; sodium lauryl sulfate; mannitol; colloidal anhydrous silica; pregelatinised maize starch; microcrystalline cellulose; aspartame; guar gum; flavour - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sugammadex sodium, quantity: 544 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sugammadex sodium, quantity: 217.6 mg (equivalent: sugammadex, qty 200 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - lenalidomide, quantity: 25 mg - capsule - excipient ingredients: povidone; mannitol; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; gelatin; titanium dioxide; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm) lenalidomide is indicated for the treatment of multiple myeloma. ,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - lenalidomide, quantity: 20 mg - capsule - excipient ingredients: povidone; mannitol; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; gelatin; iron oxide yellow; titanium dioxide; indigo carmine; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm) lenalidomide is indicated for the treatment of multiple myeloma. ,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.